A Novel Allosteric Inhibitor Targets PLK1 in Triple Negative Breast Cancer Cells

While Polo-like kinase 1 (PLK1) inhibitors have shown promise in clinical settings for treating triple-negative breast cancer tumors and other solid tumors, they are limited by their ability to bind non-selectively to the ATP kinase domain. Therefore, we sought to develop a PLK1 allosteric inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Jankiben R., Thangavelu, Prasad, Terrell, Renee M., Israel, Bridg’ette, Sarkar, Arindam Basu, Davidson, A. Michael, Zhang, Kun, Khupse, Rahul, Tilghman, Syreeta L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024838/
https://www.ncbi.nlm.nih.gov/pubmed/35454120
http://dx.doi.org/10.3390/biom12040531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024838/
https://www.ncbi.nlm.nih.gov/pubmed/35454120
http://dx.doi.org/10.3390/biom12040531

Ejemplares similares